Migraine Drugs Market 2022-2027, Industry Size, Share, Trend According to the latest report by IMARC Group, titled “Migraine Drugs Market Share: Global Industry Trends, Share, Growth, Opportunity and Forecast 2022-2027", The global migraine drugs market is expected to exhibit a CAGR of XX% during 2022-2027.
Migraine drugs refer to medications that are used to reduce the severity of migraines and prevent future attacks. A migraine is a severe, neurological disease with a debilitating headache, characterized by an intense throbbing or pulsing in one area of the head. It is accompanied by sensitivity to light, sound and smell, visual disturbances such as auras, and nausea or vomiting. Migraine drugs do not cure migraines; instead, they treat or relieve these symptoms. There are certain blood pressure medications, as well as some antidepressants, anti-seizure drugs and herbals that are used to reduce the frequency of migraines.
As the novel coronavirus (COVID-19) crisis takes over the world, we are continuously tracking the changes in the markets, as well as the industry behaviours of the consumers globally and our estimates about the latest market trends and forecasts are being done after considering the impact of this pandemic.
Global Migraine Drugs Market Trends:
According to the Migraine Trust, migraine is the third most common disease globally, with more than 10% of people getting affected by the condition worldwide. This represents the primary factor that has increased the demand for migraine drugs across the globe. Apart from this, the rising healthcare expenditure and improving reimbursement policies for migraine medications are also acting as growth-inducing factors. Besides this, healthcare providers have made significant advancements in the diagnosis and treatment of migraine. A more advanced treatment modality with mechanism-based therapies, including supraorbital transcutaneous stimulation (STS) and transcranial magnetic stimulation, has been introduced as a preventive therapy for migraine. Additionally, there are many other drugs with novel mechanisms of action or new therapeutic targets, which are in different development stages. Furthermore, for the treatment of the coronavirus disease (COVID-19), market players are testing migraine drugs, which is expected to positively influence the market. For instance, a clinical-stage biopharmaceutical company, Biohaven Pharmaceutical Holding Company Ltd., has been examining Zavegepant to treat acute migraines and has commenced the clinical trial on the same drug to mitigate the neuro-immune consequences among COVID-19 patients.
Request Free Sample Report: https://www.imarcgroup.com/migraine-drugs-market/requestsample
Global Migraine Drugs Market 2022-2027 Analysis and Segmentation:
Competitive Landscape:
The competitive landscape of the market has been studied in the report with the detailed profiles of the key players operating in the market.
Abbott Laboratories, Allergan Plc (Abbvie Inc.), Amgen Inc., AstraZeneca Plc, Bausch Health Companies Inc. (formerly Valeant Pharmaceuticals), Eisai Co. Ltd., Eli Lilly and Company, Endo International Plc, GlaxoSmithKline Plc, Johnson & Johnson, Merck & Co., Novartis AG, Pfizer Inc., Sanofi SA and Teva Pharmaceutical Industries Limited.
The report has segmented the market on the basis on region, treatment type, drug type, route of administration and distribution channel.
Breakup by Treatment Type:
- Abortive Treatment
- Preventive Treatment
Breakup by Drug Type:
- Triptans
- Ergot Alkaloids
- NSAIDs
- Acetylcholine Inhibitors/ Neurotoxins
- Ditans
- CGRP mAbs
- Others
Breakup by Route of Administration:
Breakup by Distribution Channel:
- Hospital-Based Pharmacies
- Retail Pharmacies
- Others
- Others
Breakup by Region:
- North America: (United States, Canada)
- Asia Pacific: (China, Japan,India, South Korea, Australia, Indonesia, Others)
- Europe: (Germany, France,United Kingdom, Italy, Spain, Russia, Others)
- Latin America: (Brazil, Mexico, Others)
- Middle East and Africa
Ask Analyst for Customization and Explore Full Report with TOC & List of Figure: https://www.imarcgroup.com/migraine-drugs-market
If you want latest primary and secondary data (2022-2027) with Cost Module, Business Strategy, Distribution Channel, etc. Click request free sample report, published report will be delivered to you in PDF format via email within 24 to 48 hours of receiving full payment.
Key highlights of the report:
- Market Performance (2016-2021)
- Market Outlook (2022- 2027)
- Porter’s Five Forces Analysis
- Market Drivers and Success Factors
- SWOT Analysis
- Value Chain
- Comprehensive Mapping of the Competitive Landscape
If you need specific information that is not currently within the scope of the report, we can provide it to you as a part of the customization.
About Us
IMARC Group is a leading market research company that offers management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, pharmaceuticals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
Contact Us
IMARC Group
30 N Gould St Ste R
Sheridan, WY 82801 USA
Email: Sales@imarcgroup.com
Website: https://www.imarcgroup.com